A randomised, double-blind, placebo-controlled, 4-way crossover, 2-part study investigating the pharmacodynamic effect of DSP-2230 using the ID Capsaicin and UVB models in healthy male subjects, using pregabalin and ibuprofen lysine as positive controls.

Trial Profile

A randomised, double-blind, placebo-controlled, 4-way crossover, 2-part study investigating the pharmacodynamic effect of DSP-2230 using the ID Capsaicin and UVB models in healthy male subjects, using pregabalin and ibuprofen lysine as positive controls.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs DSP 2230 (Primary) ; Ibuprofen lysinate; Pregabalin
  • Indications Neuropathic pain
  • Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Sponsors Sunovion Pharmaceuticals Europe
  • Most Recent Events

    • 30 Apr 2013 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 05 Apr 2013 Additional lead trial centre identified as reported by ISRCTN.
    • 16 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top